Dr. Martens plc

BMV:DOCS N Stock Report

Market Cap: Mex$27.9b

Dr. Martens Past Earnings Performance

Past criteria checks 2/6

Dr. Martens has been growing earnings at an average annual rate of 38%, while the Luxury industry saw earnings growing at 27.7% annually. Revenues have been growing at an average rate of 16.9% per year. Dr. Martens's return on equity is 31.9%, and it has net margins of 12.9%.

Key information

38.0%

Earnings growth rate

37.8%

EPS growth rate

Luxury Industry Growth12.9%
Revenue growth rate16.9%
Return on equity31.9%
Net Margin12.9%
Next Earnings Update30 Nov 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Dr. Martens makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:DOCS N Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 231,0001293730
31 Dec 229791533500
30 Sep 229571773470
30 Jun 229331793310
31 Mar 229081813160
31 Dec 218671183000
30 Sep 21825543040
30 Jun 21799442760
31 Mar 21773352480
31 Dec 20747612190
30 Sep 20722871910
30 Jun 20697812040
31 Mar 20672752170
31 Mar 19454171240
31 Mar 18349-6940
31 Mar 17291-11750
31 Mar 16232-12560
31 Mar 152350500
31 Mar 14164-32240

Quality Earnings: DOCS N has a high level of non-cash earnings.

Growing Profit Margin: DOCS N's current net profit margins (12.9%) are lower than last year (19.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DOCS N has become profitable over the past 5 years, growing earnings by 38% per year.

Accelerating Growth: DOCS N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DOCS N had negative earnings growth (-28.9%) over the past year, making it difficult to compare to the Luxury industry average (-13%).

Return on Equity

High ROE: DOCS N's Return on Equity (31.9%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/14 14:46
End of Day Share Price 2023/03/17 00:00
Earnings2023/03/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dr. Martens plc is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard TaylorBarclays
David RouxBofA Global Research
Louise SinglehurstGoldman Sachs